Shilpa Medicare Moves From Capacity Building Toward Growth Monetisation

Shilpa Medicare spent many years building factories and developing new medicines.

This made its costs rise before the new capacity generated enough sales.

Recently, the company’s sales and profits have started growing much faster.

Its older API business still provides the main earnings base.

New products such as ready-to-use cancer medicines have already gained market share.

Other projects, including peptides, biosimilars, ADCs and recombinant albumin, could support future growth.

However, some of these projects still need testing, approvals or successful partnerships.

A partner’s kidney-disease drug recently faced another regulatory setback, delaying possible payments to Shilpa.

Investors therefore need to decide whether the company can turn its large investments into steady profits and cash generation.